M M Levi

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. ncbi Factor v Leiden mutation in severe infection and sepsis
    Marcel Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Semin Thromb Hemost 37:955-60. 2011
  2. ncbi Influenza infection and risk of acute pulmonary embolism
    Matthijs van Wissen
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb J 5:16. 2007
  3. ncbi Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study
    Pieter R Tuinman
    Department of Intensive Care Medicine and Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Center, Meibergdreef 9, Amsterdam NL 1105 AZ, The Netherlands
    Crit Care 15:R59. 2011
  4. ncbi Recombinant human activated protein C: current insights into its mechanism of action
    Marcel Levi
    Department of Medicine, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands
    Crit Care 11:S3. 2007
  5. ncbi Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study
    Anne Cornelie J M de Pont
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
    Crit Care 9:R490-7. 2005
  6. ncbi Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study
    Marcel Schouten
    Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Room G2 130, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Crit Care 14:R145. 2010
  7. ncbi Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study
    Marcel Schouten
    Center for Experimental and Molecular Medicine CEMM, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Room G2 130, Amsterdam, The Netherlands
    Crit Care 14:R65. 2010
  8. ncbi Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage
    Lars Heslet
    Department of Intensive Care ITA 4131, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Denmark
    Crit Care 10:R177. 2006
  9. ncbi The effects of continuous venovenous hemofiltration on coagulation activation
    Catherine S C Bouman
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, PO 22660, 1100 DD Amsterdam, The Netherlands
    Crit Care 10:R150. 2006
  10. ncbi Factors that predict outcome of intensive care treatment in very elderly patients: a review
    Sophia E de Rooij
    Department of Geriatrics, Academic Medical Center, University of Amsterdam, Amsterdam
    Crit Care 9:R307-14. 2005

Detail Information

Publications160 found, 100 shown here

  1. ncbi Factor v Leiden mutation in severe infection and sepsis
    Marcel Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Semin Thromb Hemost 37:955-60. 2011
    ..In this article we review the experimental and clinical evidence regarding the relationship between the presence of a factor V Leiden mutation and the incidence and outcome of sepsis...
  2. ncbi Influenza infection and risk of acute pulmonary embolism
    Matthijs van Wissen
    Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Thromb J 5:16. 2007
    ..Influenza infections have been associated with procoagulant changes. Whether influenza infections lead to an increased risk of pulmonary embolism remains to be established...
  3. ncbi Blood transfusion during cardiac surgery is associated with inflammation and coagulation in the lung: a case control study
    Pieter R Tuinman
    Department of Intensive Care Medicine and Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Center, Meibergdreef 9, Amsterdam NL 1105 AZ, The Netherlands
    Crit Care 15:R59. 2011
    ..We hypothesized that blood transfusion is associated with changes in pulmonary and systemic inflammation and coagulation occurring in patients who do not meet the clinical diagnosis of transfusion-related acute lung injury (TRALI)...
  4. ncbi Recombinant human activated protein C: current insights into its mechanism of action
    Marcel Levi
    Department of Medicine, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands
    Crit Care 11:S3. 2007
    ..This review presents an analysis of the various mechanisms of action of rhAPC in sepsis...
  5. ncbi Recombinant human activated protein C resets thrombin generation in patients with severe sepsis - a case control study
    Anne Cornelie J M de Pont
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, The Netherlands
    Crit Care 9:R490-7. 2005
    ..The aim of the present study was to evaluate the dynamics of the anticoagulant, anti-inflammatory and pro-fibrinolytic action of rhAPC in patients with severe sepsis, by comparing rhAPC-treated patients with case controls...
  6. ncbi Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study
    Marcel Schouten
    Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Room G2 130, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Crit Care 14:R145. 2010
    ..We here determined the effect of the FVL mutation on coagulation, inflammation, bacterial outgrowth and outcome in murine pneumococcal pneumonia...
  7. ncbi Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study
    Marcel Schouten
    Center for Experimental and Molecular Medicine CEMM, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Room G2 130, Amsterdam, The Netherlands
    Crit Care 14:R65. 2010
    ..We determined the impact of lethal influenza A (H1N1) infection on systemic and pulmonary coagulation and inflammation, and the effect of recombinant mouse (rm-) APC here on...
  8. ncbi Successful pulmonary administration of activated recombinant factor VII in diffuse alveolar hemorrhage
    Lars Heslet
    Department of Intensive Care ITA 4131, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Denmark
    Crit Care 10:R177. 2006
    ..Tissue factor is expressed in the lung alveoli during inflammation and therefore pulmonary administration of human recombinant activated factor VIIa (rFVIIa) could be a rational treatment option...
  9. ncbi The effects of continuous venovenous hemofiltration on coagulation activation
    Catherine S C Bouman
    Department of Intensive Care, Academic Medical Center, University of Amsterdam, PO 22660, 1100 DD Amsterdam, The Netherlands
    Crit Care 10:R150. 2006
    ..In contrast to previous studies, CVVH was performed without anticoagulation...
  10. ncbi Factors that predict outcome of intensive care treatment in very elderly patients: a review
    Sophia E de Rooij
    Department of Geriatrics, Academic Medical Center, University of Amsterdam, Amsterdam
    Crit Care 9:R307-14. 2005
    ..This report reviews available data on factors that determine outcome, on the value of prognostic models, and on preferences regarding life-sustaining treatments in (very) elderly intensive care unit (ICU) patients...
  11. ncbi Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats
    Jorrit J Hofstra
    Laboratory of Experimental Intensive Care and Anesthesiology, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
    Crit Care 13:R145. 2009
    ..We evaluated the effect of nebulized anticoagulants on pulmonary coagulopathy and inflammation in a rat model of Streptococcus pneumoniae pneumonia...
  12. ncbi The effects of melatonin versus placebo on delirium in hip fracture patients: study protocol of a randomised, placebo-controlled, double blind trial
    Annemarieke de Jonghe
    Academic Medical Centre, University of Amsterdam, Department of Internal Medicine, Geriatrics section F4 218, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    BMC Geriatr 11:34. 2011
    ....
  13. ncbi HAE international home therapy consensus document
    Hilary J Longhurst
    Department of Immunology, Barts and The London NHS Trust, London, UK
    Allergy Asthma Clin Immunol 6:22. 2010
    ..It represents the opinion of the authors who have a wide range of expert experience in the management of HAE...
  14. ncbi 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
    Tom Bowen
    Departments of Medicine and Paediatrics, University of Calgary, Calgary, Alberta, Canada
    Allergy Asthma Clin Immunol 6:24. 2010
    ....
  15. ncbi [Volume replacement and coagulation impairment]
    M Levi
    Dipartimento di Medicina Vascolare, Medicina Interna, Centro Medico Universitario, , Amsterdam, Olanda
    Minerva Anestesiol 71:11-6. 2005
  16. ncbi Plasma and plasma components in the management of disseminated intravascular coagulation
    Marcel Levi
    Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
    Best Pract Res Clin Haematol 19:127-42. 2006
    ..These strategies comprise inhibition of tissue factor-mediated activation of coagulation or restoration of physiological anticoagulant pathways...
  17. ncbi [Deep-vein thrombosis and pulmonary embolism due to air travel]
    M Levi
    Academisch Medisch Centrum Universiteit van Amsterdam, afd Inwendige Geneeskunde, onderafd Vasculaire Geneeskunde, F 4, Meiberg dreef 9, 1105 AZ Amsterdam
    Ned Tijdschr Geneeskd 150:2474-8. 2006
    ..However, pending more solid evidence, this strategy should only be used cautiously, e.g. only in patients with a high risk of thrombosis who are planning a long flight...
  18. ncbi Bidirectional relation between inflammation and coagulation
    Marcel Levi
    Department of Internal Medicine (F-4, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Circulation 109:2698-704. 2004
  19. ncbi Critical bleeding in surgery: conventional therapy and new prospects
    M Levi
    Department of Vascular Medicine Internal Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Minerva Anestesiol 70:267-71. 2004
    ....
  20. ncbi Coagulation in sepsis: all bugs bite equally
    Marcel Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Crit Care 8:99-100. 2004
    ..There is no correlation between the type of microorganism that has caused the infection and the presence or severity of the coagulation disorder...
  21. ncbi The coagulant response in sepsis
    Marcel Levi
    Department of Medicine F4 219, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Clin Chest Med 29:627-42, viii. 2008
    ..Strategies to inhibit coagulation activation may theoretically be justified and are being evaluated in clinical studies...
  22. ncbi New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology
    Marcel Levi
    Department of Internal Medicine Vascular Medicine, Intensive Care, Laboratory of Experimental Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Ann Med 36:41-9. 2004
    ..These strategies comprise inhibition of tissue factor-mediated activation of coagulation or restoration of physiological anticoagulant pathways, for example by means of the administration of recombinant human activated protein C...
  23. ncbi Thrombocytopenia in critically ill patients
    Marcel Levi
    Department Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands
    Semin Thromb Hemost 34:417-24. 2008
    ....
  24. ncbi Current understanding of disseminated intravascular coagulation
    Marcel Levi
    Department of Vascular Medicine and Internal Medicine, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Br J Haematol 124:567-76. 2004
  25. ncbi Sepsis and disseminated intravascular coagulation
    Marcel Levi
    Department of Internal Medicine Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Thrombolysis 16:43-7. 2003
    ....
  26. ncbi Emergency reversal of antithrombotic treatment
    Marcel Levi
    Department of Medicine F 4, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
    Intern Emerg Med 4:137-45. 2009
    ..A limitation of this new class of anticoagulants may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs, although in some cases the administration of recombinant factor VIIa may be an option...
  27. ncbi Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)
    Marcel Levi
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Am J Respir Crit Care Med 176:483-90. 2007
    ..Biological plausibility exists for heparin to reduce DrotAA efficacy and/or increase bleeding...
  28. ncbi Use of recombinant factor VIIa in the perioperative period
    M Levi
    Dept of Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Hamostaseologie 29:68-70. 2009
    ..Its exact place in surgery warrants further clinical trials in various situations that will also more precisely determine the safety of this intervention...
  29. ncbi Prevention and treatment of bleeding by pro-hemostatic treatment strategies
    Marcel Levi
    Department of Vascular Medicine Internal Medicine, University of Amsterdam, The Netherlands
    Wien Med Wochenschr 153:421-5. 2003
    ..There is a need for more systematic and adequately controlled clinical observations to better establish the efficacy and safety of pro-hemostatic interventions...
  30. ncbi Activated protein C in sepsis: a critical review
    Marcel Levi
    Department of Internal Medicine and Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Curr Opin Hematol 15:481-6. 2008
    ..Initial clinical studies with activated protein C in patients with sepsis showed a reduction of 28-day mortality. However, subsequent studies did cast some doubt on the efficacy and also the safety of this treatment...
  31. ncbi Recombinant factor VIIa: a general hemostatic agent? Not yet
    M Levi
    Department of Internal Medicine and Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Haemost 2:1695-7. 2004
  32. ncbi Self-management of anticoagulation
    Marcel Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Expert Rev Cardiovasc Ther 6:979-85. 2008
    ..Moreover, treatment-related patient satisfaction and quality of life improves in patients performing self-management of anticoagulation...
  33. ncbi Tissue factor in infection and severe inflammation
    Marcel Levi
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Semin Thromb Hemost 32:33-9. 2006
    ..There is increasing experimental evidence that TF inhibition may have beneficial effects in disease states in which the combination of coagulation and inflammation plays a prominent role...
  34. ncbi [Thromboprophylaxis for cerebrovascular disorders: acetylsalicylic acid remains the cornerstone]
    M Levi
    Academisch Medisch Centrum Universiteit van Amsterdam, afd Inwendige Geneeskunde, onderafd Vasculaire Geneeskunde, F 4, Meibergdreef 9, 1105 AZ Amsterdam
    Ned Tijdschr Geneeskd 152:423-5. 2008
    ..In the ESPRIT trial, the combination of acetylsalicylic acid and dipyridamole provided a modest benefit over acetylsalicylic acid alone in the prevention of (recurrent) ischaemic stroke...
  35. ncbi Antithrombin in sepsis revisited
    Marcel Levi
    Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Crit Care 9:624-5. 2005
    ....
  36. ncbi Platelets
    Marcel Levi
    Department of Internal Medicine (F-4, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Crit Care Med 33:S523-5. 2005
  37. ncbi Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency
    Marcel Levi
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    J Allergy Clin Immunol 117:904-8. 2006
    ..The concentrate should be administered intravenously and hence needs to be administered by health care professionals, which might cause considerable delay in treatment and inconvenience for patients...
  38. ncbi Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based
    Marcel Levi
    Department of Internal Medicine Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Blood 111:4471-6. 2008
    ..VKAs are often prescribed to patients who would not have qualified for clinical trials, and in these patients a careful consideration should be made regarding the expected efficacy and the risk of bleeding...
  39. ncbi Cancer and thrombosis
    Marcel Levi
    University of Amsterdam and Department of Medicine, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
    Clin Adv Hematol Oncol 1:668-71. 2003
    ..The pathogenetic pathways that play a role in the cancer-associated coagulopathy have been identified in recent years...
  40. ncbi Metabolic modulation of inflammation-induced activation of coagulation
    Marcel Levi
    Department of Vascular Medicine Internal Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Semin Thromb Hemost 34:26-32. 2008
    ..There are indications that this modulatory role of metabolic factors in inflammation and coagulation may also have an impact on clinical outcome in various disease states...
  41. ncbi Platelets in sepsis
    Marcel Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Hematology 10:129-31. 2005
    ..In addition, in this situation platelets may be directly involved in the inflammatory response by releasing inflammatory mediators and growth factors...
  42. ncbi Coagulation abnormalities in critically ill patients
    Marcel Levi
    Department of Vascular Medicine and Internal Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands
    Crit Care 10:222. 2006
    ....
  43. ncbi Clinical relevance of the effects of plasma expanders on coagulation
    Marcel Levi
    Department of Vascular Medicine Internal Medicine, Amsterdam, The Netherlands
    Semin Thromb Hemost 33:810-5. 2007
    ..e., > 1.5 L) are infused or if the patient has a concomitant or preexistent hemostatic impairment...
  44. ncbi The inflammation-coagulation axis as an important intermediate pathway in acute lung injury
    Marcel Levi
    Department of Vascular Medicine and Internal Medicine F 4, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Crit Care 12:144. 2008
    ....
  45. ncbi Disseminated intravascular coagulation: What's new?
    Marcel Levi
    Department of Vascular and Internal Medicine F 4, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Crit Care Clin 21:449-67. 2005
    ....
  46. ncbi [Perioperative thromboprophylaxis--for the immobilisation period, potential extension beyond hospitalisation]
    M Levi
    Academisch Medisch Centrum Universiteit van Amsterdam, afd Inwendige Geneeskunde, onderafd, Vasculaire Geneeskunde, F 4, Meiberg dreefg, 1105 AZ Amsterdam
    Ned Tijdschr Geneeskd 149:2490-1. 2005
    ....
  47. ncbi Epidemiology and management of bleeding in patients using vitamin K antagonists
    M Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Haemost 7:103-6. 2009
    ..In case of serious bleeding complications in a patient who uses vitamin K antagonists, this anticoagulant treatment can be quickly reversed by administration of vitamin K or coagulation factor concentrates...
  48. ncbi Therapeutic options in patients with DIC and cancer
    Marcel Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Pathophysiol Haemost Thromb 33:46-7. 2003
  49. ncbi Periprocedural reversal and bridging of anticoagulant treatment
    M Levi
    Department of Vascular Medicine and Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Neth J Med 69:268-73. 2011
    ....
  50. ncbi [Self-monitoring and self dosing of oral anticoagulant therapy with vitamin K antagonists]
    M Levi
    afd Inwendige Geneeskunde, Academisch Medisch Centrum, Meibergdreef 9, 1105 AZ Amsterdam
    Ned Tijdschr Geneeskd 145:2313-7. 2001
    ....
  51. ncbi [Physical diagnostics--peripheral arterial diseases]
    M Levi
    Academisch Medisch Centrum Universiteit van Amsterdam, Meibergdfeef 9, 1105 AZ Amsterdam
    Ned Tijdschr Geneeskd 145:902-5. 2001
    ..Peripheral arterial disease is unlikely when this index is normal. However, a low ankle-brachial index necessitates further investigations to determine possible arterial insufficiency in the lower extremities...
  52. ncbi Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies
    M Levi
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam
    Semin Thromb Hemost 27:569-75. 2001
    ....
  53. ncbi Hematologic failure
    Marcel Levi
    Department of Vascular Medicine Internal Medicine, University of Amsterdam, The Netherlands
    Semin Respir Crit Care Med 32:651-9. 2011
    ..Hence, a proper differential diagnosis and initiation of adequate (supportive) treatment strategies are crucial to reduce morbidity and mortality in critically ill patients with coagulation abnormalities...
  54. ncbi Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees
    M Levi
    Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Laboratory of Experimental Medicine, and Department of Pulmonology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Am J Respir Crit Care Med 158:92-8. 1998
    ..The endotoxin-induced effects on bronchoalveolar coagulation appears to be mediated by IL-6, whereas TNF-alpha seems to be the pivotal mediator of the endotoxin-induced depression of bronchoalveolar fibrinolysis...
  55. ncbi Systemic versus localized coagulation activation contributing to organ failure in critically ill patients
    Marcel Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Semin Immunopathol 34:167-79. 2012
    ..Interestingly, apart from the overall systemic responses, a differential local response in various vascular beds related to specific organs may occur...
  56. ncbi Coagulopathy and platelet disorders in critically ill patients
    M Levi
    Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Minerva Anestesiol 76:851-9. 2010
    ..Hence, a proper differential diagnosis and the initiation of adequate (supportive) treatment strategies are crucial to reduce morbidity and mortality in critically ill patients with coagulation abnormalities...
  57. ncbi Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits
    M Levi
    Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Academic Medical Center, University of Amsterdam, The Netherlands
    Nat Med 5:107-11. 1999
    ....
  58. ncbi DIC: which laboratory tests are most useful
    Marcel Levi
    Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Blood Rev 25:33-7. 2011
    ....
  59. ncbi Safety of recombinant activated factor VII in randomized clinical trials
    Marcel Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    N Engl J Med 363:1791-800. 2010
    ..To address this issue, we evaluated the rate of thromboembolic events in all published randomized, placebo-controlled trials of rFVIIa used on an off-label basis...
  60. ncbi [Long flights and the risk of venous thrombosis]
    M Levi
    Academisch Medisch Centrum, afd Inwendige Geneeskunde, onder afd Vasculaire Geneeskunde, Meibergdreef 9, 1105 AZ Amsterdam
    Ned Tijdschr Geneeskd 145:292-4. 2001
    ..Furthermore, all air travellers should be advised to keep moving during long flights and to drink plenty, preferably non-alcoholic beverages...
  61. ncbi Treatment with recombinant human activated protein C: one size does not fit all
    Marcel Levi
    Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Crit Care 15:105. 2011
    ..This may potentially translate to a better clinical outcome in patients with severe sepsis, although that was not directly shown in this trial...
  62. ncbi Anticoagulants. Old and new
    M Levi
    Dept of Medicine, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
    Hamostaseologie 31:229-35. 2011
    ..For the newer anticoagulants, quick reversal strategies are more cumbersome, although some interventions, including prothrombin complex concentrates, show promising results in initial experimental studies...
  63. ncbi [Blind spots of the diagnostic hemostasis screen]
    M Levi
    Academisch Medisch Centrum, afd Inwendige Geneeskunde, Amsterdam
    Ned Tijdschr Geneeskd 144:457-60. 2000
    ..In patients with a strong suspicion of a coagulation disorder such defects should be specifically tested for...
  64. ncbi Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents
    M Levi
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Haemost 9:1705-12. 2011
    ..A limitation of these new agents may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs, although experimental studies show hopeful results for some of these agents...
  65. ncbi Recombinant anticoagulant factors for adjunctive treatment of sepsis
    Marcel Levi
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Semin Thromb Hemost 36:550-7. 2010
    ..Restoration of these anticoagulant pathways is currently evaluated in several clinical studies. Production of these physiological anticoagulants by recombinant technology greatly facilitates this adjunctive treatment strategy...
  66. ncbi Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints
    M Levi
    Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, The Netherlands
    Lancet 354:1940-7. 1999
    ....
  67. ncbi All heparins are equal, but some are more equal than others
    M Levi
    Department of Internal Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    J Thromb Haemost 1:884-5. 2003
  68. ncbi Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives
    Marcel Levi
    Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Semin Thromb Hemost 35:527-42. 2009
    ....
  69. ncbi Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice
    Marcel Levi
    Department of Vascular Medicine Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
    Blood 101:4823-7. 2003
    ....
  70. ncbi [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia]
    M Levi
    Academisch Medisch Centrum Universiteit van Amsterdam, afd Inwendige Geneeskunde, Meibergdreef 9, 1105 AZ Amsterdam
    Ned Tijdschr Geneeskd 146:2534-7. 2002
    ....
  71. ncbi Haemostasis and thrombosis: new developments in treatment strategies
    M Levi
    Department of Internal Medicine F 4, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Neth J Med 61:8-12. 2003
    ..In some cases this also results in a (relatively modest) increase in the risk of bleeding. The clinical use of the new compounds is often much more convenient than that of the currently available antithrombotic modalities...
  72. ncbi Inflammation and coagulation
    Marcel Levi
    Department of Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef, Amsterdam, The Netherlands
    Crit Care Med 38:S26-34. 2010
    ..Conversely, activated coagulation proteases may affect specific cellular receptors on inflammatory cells and endothelial cells and thereby modulate the inflammatory response...
  73. ncbi The coagulant response in sepsis and inflammation
    M Levi
    Department of Medicine and Vascular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Hamostaseologie 30:10-2, 14-6. 2010
    ..Increasing knowledge on the various mechanisms underlying activation of inflammation and coagulation may lead to better (adjunctive) management strategies in critically ill patients...
  74. ncbi Adequate thromboprophylaxis in critically ill patients
    Marcel Levi
    Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
    Crit Care 14:142. 2010
    ..Anti-factor Xa levels thought to be required for adequate thromboprophylaxis are observed only at doses of enoxaparin that are one and a half times higher than the conventional dose (40 mg)...
  75. ncbi Therapeutic intervention in disseminated intravascular coagulation: have we made any progress in the last millennium?
    Marcel Levi
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Blood Rev 16:S29-34. 2002
    ..These strategies comprise inhibition of tissue factor-mediated activation of coagulation or restoration of physiological anticoagulant pathways, by means of the administration of antithrombin concentrate or (activated) protein C...
  76. ncbi Measuring activated protein C in plasma to assess its role as a critical modulator of coagulation and inflammation
    M Levi
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    J Thromb Haemost 1:643-4. 2003
  77. ncbi Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management
    M M Levi
    Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Neth J Med 68:68-76. 2010
    ....
  78. ncbi Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation
    G Choi
    Department of Intensive Care Medicine, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Eur Respir J 30:423-8. 2007
    ..Natural inhibitors of coagulation prevent bronchoalveolar activation of coagulation, but do not induce major alterations of the pulmonary inflammatory response in rat endotoxaemia...
  79. ncbi Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats
    Goda Choi
    Department of Intensive Care Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Crit Care Med 35:1362-8. 2007
    ..We investigated the role of the protein C system in pneumonia caused by Pseudomonas aeruginosa, the organism that is predominantly involved in ventilator-associated pneumonia...
  80. ncbi Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteers
    Nico A Maris
    Department of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Thromb Haemost 93:1036-40. 2005
    ..Inhalation of LPS by healthy humans reproduces major features of the procoagulant response to inflammatory and infectious lung diseases and may be used as a novel model to evaluate pathogenetic mechanisms and new interventions...
  81. ncbi Salmeterol enhances pulmonary fibrinolysis in healthy volunteers
    Nico A Maris
    Center for Experimental and Molecular Medicine Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Crit Care Med 35:57-63. 2007
    ..Although salmeterol, a beta2-adrenoceptor agonist with profound bronchodilatory properties, has been studied extensively, the effects of this compound on the pulmonary hemostatic balance are not elucidated...
  82. ncbi Inhibition of coagulation and inflammation by activated protein C or antithrombin reduces intestinal ischemia/reperfusion injury in rats
    Ivo G Schoots
    Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands
    Crit Care Med 32:1375-83. 2004
    ..These observations suggest that activated protein C or antithrombin reduces ischemia/reperfusion-induced intestinal injury, both through their anticoagulant and anti-inflammatory effects...
  83. ncbi Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis
    Suzanne Q van Veen
    Department of Surgery, Surgical Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Shock 27:534-41. 2007
    ..Survival rate was unaffected likely due to adverse changes in IL-12 and IL-10 levels...
  84. ncbi Tissue factor and coronary artery disease
    Arno H M Moons
    Department of Cardiology, Academic Medical Center, Room F3-236, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Cardiovasc Res 53:313-25. 2002
    ..In this review, we present the current knowledge on the role of tissue factor in atherosclerosis, arterial intervention and potential pharmacological approaches, with focus on acute coronary syndromes...
  85. ncbi Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation
    Kamran Bakhtiari
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Crit Care Med 32:2416-21. 2004
    ..An aPTT waveform analysis is an interesting and promising tool to assist in the diagnostic management of DIC...
  86. ncbi Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia
    Anita W Rijneveld
    Center of Infection and Immunity Amsterdam, Laboratory of Experimental Internal Medicine, Department of Pulmonology, University of Amsterdam, The Netherlands
    Crit Care Med 34:1725-30. 2006
    ..CONCLUSIONS: These data suggest that TF-FVIIa activity contributes to activation of coagulation in the lung during pneumococcal pneumonia but does not play an important role in the antibacterial host defense in this murine model...
  87. ncbi Effects of clopidogrel on the rebound hypercoagulable state after heparin discontinuation in patients with acute coronary syndromes
    Marcello Di Nisio
    J Am Coll Cardiol 46:1582-3. 2005
  88. ncbi Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees
    Arno H M Moons
    Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
    Thromb Haemost 88:627-31. 2002
    ..These results suggest that rNAPc2 may be a promising therapeutic option to inhibit coagulation activation in patients with sepsis...
  89. ncbi Disseminated intravascular coagulation
    Marcel Levi
    Department of Vascular Medicine and Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Crit Care Med 35:2191-5. 2007
    ..To review the current knowledge on the clinical manifestation, pathogenesis, diagnosis, and management of disseminated intravascular coagulation (DIC)...
  90. ncbi Inflammation, endothelium, and coagulation in sepsis
    Marcel Schouten
    Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands
    J Leukoc Biol 83:536-45. 2008
    ....
  91. ncbi High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans
    Rakesh S Birjmohun
    Academic Medical Center of Amsterdam, Department of Vascular Medicine, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Arterioscler Thromb Vasc Biol 27:1153-8. 2007
    ..In the present study, we evaluated whether there is a relation between HDL and sensitivity toward a low-dose endotoxin challenge...
  92. ncbi Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure
    Jean Francois Dhainaut
    Department of Intensive Care, Cochin Hospital, AP HP, Cochin Institute, Cochin Port Royal Medical School, Paris V University, Paris, France
    Crit Care Med 33:341-8. 2005
    ..To determine whether changes in coagulation biomarkers during the first day of severe sepsis correlate with progression from single to multiple organ failure and subsequent death...
  93. ncbi Early procoagulant shift in the bronchoalveolar compartment of patients with secondary peritonitis
    J W Olivier Van Till
    Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands
    J Infect Dis 194:1331-9. 2006
    ..This imbalance may be associated with reduced oxygen delivery and an adverse outcome in secondary peritonitis...
  94. ncbi Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis
    Suzanne Q van Veen
    Department of Surgery (Surgical Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Crit Care Med 34:2799-805. 2006
    ..03). CONCLUSIONS: Peritoneal lavage with activated protein C may rebalance coagulation and fibrinolysis within compartments and improve survival in polymicrobial peritonitis...
  95. ncbi Two-way interactions between inflammation and coagulation
    Marcel Levi
    Department of Internal Medicine and Laboratory of Experimental Internal Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Trends Cardiovasc Med 15:254-9. 2005
    ..This review focuses on the present understanding of the bidirectional relationship between inflammation and coagulation...
  96. ncbi Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury
    Goda Choi
    Dept of Intensive Care Medicine, Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Anesthesiology 105:689-95. 2006
    ..The authors sought to determine the effects of mechanical ventilation on the alveolar hemostatic balance in patients without preexistent lung injury...
  97. ncbi Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
    T van der Poll
    Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, The Netherlands
    J Exp Med 179:1253-9. 1994
    ..IL-6 is, however, an important intermediate factor in activation of coagulation in low grade endotoxemia in chimpanzees...
  98. ncbi Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats
    D J van Westerloo
    Center for Infection and Immunity Amsterdam, CINIMA, Amsterdam, The Netherlands
    J Thromb Haemost 4:1997-2002. 2006
    ..CONCLUSION: These data illustrate a thus far unrecognized effect of VNS and suggest that the cholinergic anti-inflammatory pathway not only impacts on inflammation but also on the coagulant-anticoagulant balance...
  99. ncbi Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees
    B Kuipers
    Center of Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, University of Amsterdam, The Netherlands
    J Immunol 152:2438-46. 1994
    ..PAF does not seem to be an important intermediate factor in endotoxin-induced neutrophilia or neutrophil degranulation...
  100. ncbi Interleukin 10 release during endotoxaemia in chimpanzees: role of platelet-activating factor and interleukin 6
    T van der Poll
    Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    Scand J Immunol 43:122-5. 1996
    ..IL-10 release elicited by injection of endotoxin is not mediated by PAF or IL6...
  101. ncbi Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient
    M Levi
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Crit Care 16:167-77. 2001
    ..Studies of other novel therapeutic avenues are still ongoing. Future efforts may be directed at combining 2 or more agents to achieve prompt and successful reversal of DIC...